Tumor Necrosis Factor Inhibitor Use Increases Birthweight in Pregnant Women With Rheumatoid Arthritis Independently of the Soluble Fms‐Like Tyrosine Kinase‐1/Placental Growth Factor Ratio

Autor: Cornelia H. Quaak, Anna C. M. Kluivers, Sara J. Baart, Hieronymus T. W. Smeele, Rugina I. Neuman, Langeza Saleh, Willy Visser, A. H. Jan Danser, Radboud J. E. M. Dolhain

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 7 (2024)

Background To study whether the use of TNF (tumor necrosis factor) inhibitors (TNFi) by pregnant women with rheumatoid arthritis affects sFlt‐1 (soluble Fms‐like tyrosine kinase‐1), PlGF (placental growth factor), or their impact on birthweight

Externí odkaz: https://doaj.org/article/162d419859824385a401fc39db1d5b3e

IL-6 but Not TNFα Levels Are Associated With Time to Pregnancy in Female Rheumatoid Arthritis Patients With a Wish to Conceive

Autor: Margot Bongenaar, Hieronymus T. W. Smeele, Erik Lubberts, Radboud J. E. M. Dolhain

Publikováno v: Frontiers in Pharmacology, Vol 11 (2020)

Fertility issues are common amongst women with rheumatoid arthritis (RA). Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα), known key players in RA pathogenesis, have been associated with reproductive disorders. This study investigates th

Externí odkaz: https://doaj.org/article/164f4f9cd7264108bdd190e0dc8aa37c

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy

Autor: Gertjan Wolbink, Radboud J E M Dolhain, Hieronymus T W Smeele, Erik Kemper, Theo Rispens, Ineke Hubertina Crijns, Nafise Ghalandari

Publikováno v: Annals of the Rheumatic Diseases, 81(3), 402-405. BMJ Publishing Group
Annals of the rheumatic diseases, 81(3), 402-405. BMJ Publishing Group
Ghalandari, N, Kemper, E, Crijns, I H, Wolbink, G, Rispens, T, Smeele, H T & Dolhain, R J 2022, ' Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy ', Annals of the Rheumatic Diseases, vol. 81, no. 3, pp. 402-405 . https://doi.org/10.1136/annrheumdis-2021-221036

Background: Increasing evidence suggests that TNF inhibitors (TNFi) are safe to use during pregnancy1. A drawback of TNFi use during pregnancy is active transport across the placenta, which is affected by the structure of the TNFi1. The European Leag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5acc7e391c68e3eab7bac1160cce08
https://doi.org/10.1136/annrheumdis-2021-221036

Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring

Autor: Hieronymus T W Smeele, Esther Röder, Annemarie G M G J Mulders, Eric A P Steegers, Radboud J E M Dolhain

Publikováno v: Annals of the Rheumatic Diseases, 81(10), 1367-1373. BMJ Publishing Group

ObjectivesTo study pregnancy outcomes in a closely monitored, well-defined cohort of women with rheumatoid arthritis (RA). In particular, pregnancy outcomes of women that used a TNFi during pregnancy.MethodsPatients were derived from a prospective st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d834a680a772a04707288b48a410548
https://pubmed.ncbi.nlm.nih.gov/35817469

Comment on

Autor: A.H. Jan Danser, Hieronymus T W Smeele, Rugina I. Neuman, Radboud J E M Dolhain, Willy Visser, Cecile Berenguer

Publikováno v: Rheumatology (Oxford, England), 61(2), e54-e55. Oxford University Press

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f05818840be370f79706fac14833fee
https://doi.org/10.1093/rheumatology/keab769